PL374814A1 - Ulepszony system podawania przezskórnego rotigotyny - Google Patents

Ulepszony system podawania przezskórnego rotigotyny

Info

Publication number
PL374814A1
PL374814A1 PL03374814A PL37481403A PL374814A1 PL 374814 A1 PL374814 A1 PL 374814A1 PL 03374814 A PL03374814 A PL 03374814A PL 37481403 A PL37481403 A PL 37481403A PL 374814 A1 PL374814 A1 PL 374814A1
Authority
PL
Poland
Prior art keywords
rotigotine
matrix
tds
delivery system
transdermal delivery
Prior art date
Application number
PL03374814A
Other languages
English (en)
Other versions
PL217079B1 (pl
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Publication of PL374814A1 publication Critical patent/PL374814A1/pl
Publication of PL217079B1 publication Critical patent/PL217079B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL374814A 2002-07-30 2003-07-28 System przezskórnego podawania leków (TDS) zawierający rotigotynę oraz zastosowanie TDS do otrzymania leku zawierającego rotigotynę PL217079B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine

Publications (2)

Publication Number Publication Date
PL374814A1 true PL374814A1 (pl) 2005-10-31
PL217079B1 PL217079B1 (pl) 2014-06-30

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374814A PL217079B1 (pl) 2002-07-30 2003-07-28 System przezskórnego podawania leków (TDS) zawierający rotigotynę oraz zastosowanie TDS do otrzymania leku zawierającego rotigotynę

Country Status (19)

Country Link
EP (2) EP1386605A1 (pl)
JP (2) JP4837916B2 (pl)
KR (1) KR101016838B1 (pl)
CN (2) CN101953819A (pl)
AT (1) ATE322263T1 (pl)
AU (1) AU2003258539B2 (pl)
BR (1) BR0313091A (pl)
CA (1) CA2491366A1 (pl)
DE (1) DE60304477T2 (pl)
DK (1) DK1524975T3 (pl)
ES (1) ES2256780T3 (pl)
IL (1) IL165918A0 (pl)
MX (1) MXPA05000350A (pl)
NO (1) NO333297B1 (pl)
PL (1) PL217079B1 (pl)
PT (1) PT1524975E (pl)
SI (1) SI1524975T1 (pl)
WO (1) WO2004012730A1 (pl)
ZA (1) ZA200500252B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
AU2009302853B2 (en) * 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
LT3257504T (lt) * 2009-12-22 2024-08-26 UCB Biopharma SRL Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui
ES2608782T3 (es) 2010-04-30 2017-04-17 Teikoku Pharma Usa, Inc. Composiciones transdérmicas de propinilaminoindano
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
MX2015000049A (es) * 2012-07-05 2015-04-08 Sk Chemicals Co Ltd Preparacion absorbible transdermicamente que contiene rotigotina.
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
US20160199316A1 (en) 2013-06-14 2016-07-14 Tesa Labtec Gmbh Three-layer transdermal therapy system (tts)
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
CN106456566B (zh) * 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
ATE246919T1 (de) * 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
ZA200500252B (en) 2006-01-25
KR101016838B1 (ko) 2011-02-22
JP5564469B2 (ja) 2014-07-30
DE60304477D1 (de) 2006-05-18
WO2004012730A1 (en) 2004-02-12
EP1386605A1 (en) 2004-02-04
NO333297B1 (no) 2013-04-29
EP1524975B1 (en) 2006-04-05
DK1524975T3 (da) 2006-07-31
IL165918A0 (en) 2006-01-15
JP4837916B2 (ja) 2011-12-14
DE60304477T2 (de) 2006-12-14
ES2256780T3 (es) 2006-07-16
EP1524975B9 (en) 2012-02-22
EP1524975A1 (en) 2005-04-27
KR20050056942A (ko) 2005-06-16
CA2491366A1 (en) 2004-02-12
AU2003258539B2 (en) 2008-08-21
CN1671375A (zh) 2005-09-21
CN101953819A (zh) 2011-01-26
SI1524975T1 (sl) 2006-06-30
PL217079B1 (pl) 2014-06-30
JP2011219485A (ja) 2011-11-04
BR0313091A (pt) 2005-06-21
JP2005535687A (ja) 2005-11-24
NO20050472L (no) 2005-01-27
MXPA05000350A (es) 2005-03-31
AU2003258539A1 (en) 2004-02-23
ATE322263T1 (de) 2006-04-15
PT1524975E (pt) 2006-07-31

Similar Documents

Publication Publication Date Title
IL165918A0 (en) Improved transdermal delivery system for the administration of rotigotine
IL165917A0 (en) Improved transdermal delivery system
MXPA04001676A (es) Sistema terapeutico transdermico con fentanilo o sustancias relacionadas.
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
MY105347A (en) Transdermal therapeutic system comprising as active component buprenorphine
IE800059L (en) Polymeric diffusion matrix
NZ541807A (en) UV stable transdermal therapeutic plaster
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
CA2387143A1 (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
RU2009137122A (ru) Устройство для трансдермального введения бисопролола
AU2108300A (en) Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids
MY110391A (en) Nitroglycerin-containing patch, a process for the production and the use thereof
ATE214606T1 (de) Transdermales therapeutisches system mit dem wirkstoff scopolaminbase
KR100387397B1 (pl)
DE20221160U1 (de) Transdermales therapeutisches System mit Fentanyl bzw. verwandten Substanzen

Legal Events

Date Code Title Description
RECP Rectifications of patent specification